

November 21, 2025

Company name Sysmex Corporation
Representative President Kaoru Asano

(Stock Code: 6869)

Inquiries Takashi Hatakeda, Executive Vice

President of Corporate Communication

Division

(Telephone: +81-78-265-0500)

Notice Concerning Absorption-Type Merger (Simplified/Short-Form Merger) of Wholly Owned Subsidiary

Sysmex Corporation (the "Company") hereby announces that a meeting of the Board of Directors held on November 21, 2025 resolved to absorb its wholly owned subsidiary, Sysmex Medica Co., Ltd. (hereinafter "Sysmex Medica") and have entered into a merger agreement.

Since this is a simplified absorption-type merger involving a wholly owned subsidiary, some disclosure items and details have been omitted.

1. Purpose of the merger

Sysmex Medica is a company that assembles units of diagnostic instruments. The Company decided to absorb Sysmex Medica to optimize the equipment production process within the Group and to enhance efficiency and productivity.

2. Summary of the merger

(1) Timetable for the merger

Date of resolution at the meeting of the Board of Directors	November 21, 2025
Date of conclusion of the agreement	November 21, 2025
Commencement date (Effective date)	April 1, 2026 (scheduled)

(Note) Since this is a simplified merger pursuant to Article 796, paragraph (2) of the Companies Act of Japan for the Company and is also a short-form merger pursuant to Article 784, paragraph (1) of the Companies Act for the Sysmex Medica, each

company will not hold a general meeting of shareholders to approve the merger agreement.

(2) Form of the merger

The merger will be conducted as an absorption-type merger, with the Company as the surviving company, and Sysmex Medica will be dissolved.

(3) Details of allotment related to the merger

Since the merger is a merger with a wholly owned subsidiary of the Company, there will be no issuance of new shares, no allotment of money, etc. related to the merger.

(4) Handling of share acquisition rights and bonds with share acquisition rights in connection with the merger

Not applicable.

3. Overview of companies involved in the merger

	Company surviving the absorption-type merger	Company disappearing in the absorption-type merger		
(1) Name	Sysmex Corporation	Sysmex Medica Co., Ltd.		
(2) Location	1-5-1 Wakinohama-Kaigandori, Chuo-	323-3 Miyaoki, Yumesaki-Cho,		
	ku, Kobe, Hyogo	Himeji, Hyogo		
(3) Job title and name	President	President and CEO		
of representative	Kaoru Asano	Emiko Takahashi		
(4) Line of businesses	Development, manufacture, sales and	Assembly of diagnostic instrument		
	export/import of diagnostic instruments,	units		
	reagents and related software			
(5) Share capital	14,887 millions of yen	20 millions of yen		
	(As of March 31, 2025)	(As of March 31, 2025)		
(6) Date of	February 20, 1968	March 7, 1978		
establishment				
(7) Number of issued	629,473,176 shares	400 shares		
shares	(As of March 31, 2025)	(As of March 31, 2025)		
(8) Fiscal year-end	March 31	March 31		
(9) Major shareholders	The Master Trust Bank of 12.4%	Sysmex Corporation 100%		
and percentage of	Japan, Ltd. (Trust Account)			
share-holding	Nakatani Foundation 6.2%			

(As of March 31, 2025)	Custody Bank of Japan, Ltd. 6.0% (Trust Account)			
	The Kobe Yamabuki Foundation	5.7%		
	Nakatani Kosan, Ltd.	5.5%		
(10) Operating results	Fiscal year ended March 31, 2025		Fiscal year ended March 31, 2025	
and financial	(Consolidated, IFRS)		(Non-consolidated, JGAAP)	
positions for the	Equity attributable to	463,776	Net assets	622
most recent fiscal	owners of the parent	millions of yen		millions of yen
year	Total assets	665,268	Total assets	935
		millions of yen		millions of yen
	Equity attributable to	743.71 yen	Net assets per share	1,555,174.55
	owners of the parent			yen
	per share			
	Net sales	508,643	Net sales	2,482
		millions of yen		millions of yen
	Operating profit	87,583	Operating profit	196
		millions of yen		millions of yen
	Profit before tax	79,221	Ordinary profit	198
		millions of yen		millions of yen
	Profit attributable to	53,669	Net income	134
	owners of the parent	millions of yen		millions of yen
	Earnings per share	86.07 yen	Net income per	336,684.12
	(basic)		share	yen

(Note: Percentage of shareholding excludes treasury stock.)

4. Status after the merger

There will be no changes in the name, location, job title and name of representative, description of business, share capital and fiscal year-end of the Company after the merger.

5. Future outlook

Since this is a merger with a wholly owned subsidiary of the Company, the impact on the Company consolidated financial results will be minor.

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.